GRIN Therapeutics Announces First Patient Dosed in Global Phase 3 Beeline Trial of Investigational Radiprodil for GRIN-Related Neurodevelopmental Disorder
By SquaredTown on January 9, 2026
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global Phase 3 Beeline trial of investigational...